Vertex Pharmaceuticals Incorporated (VRTX)

From the record

Vertex Pharmaceuticals Incorporated's filings since 2017 show 1 warning event: a debt default or acceleration notice (8-K item 2.04, the latest 2019-09-17) (its current reports).

From the record

Vertex Pharmaceuticals Incorporated's 10 filed years say what it did: revenue went from $1.7 billion in fiscal 2016 to $12 billion in fiscal 2025, up 24.2% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 8 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Vertex Pharmaceuticals Incorporated's diluted share count shrank about 0.1% a year, and dividends and buybacks returned about 54% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 94 sales (94 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-10 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Vertex Pharmaceuticals Incorporated earned about 21 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 40 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).

From the record

Vertex Pharmaceuticals Incorporated's standing among 315 graded names in its industry family: revenue of $12 billion in fiscal 2025 ranks in the top 4% by size; a net margin of 32.9% ranks in the top 8%; revenue growth of 10.3% a year over the last 3 filed years ranks in the top 47% (its annual reports).

From the record

Vertex Pharmaceuticals Incorporated's leadership, from its insiders' filings and its current reports: the chief executive on the record is Kewalramani, Reshma (CEO & President, as filed), filing under that title since 2020-05-08, 6.5 years (top 32% of its family); the 24 officers and directors filing in the last fifteen months have been on the record a median of 6.1 years (top 39%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 24 people in charge now (top 29%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Vertex Pharmaceuticals Incorporated's room to grow, from the newest filed statements (fiscal 2025): cash of $5.1 billion against no long-term debt tagged leaves 19.8% of its assets as net cash, bottom 39% of its family; cash from operations less capital spending is 26.6% of revenue (top 9%); a gross margin of 86.2% (top 25%); research spending of 32.6% of revenue (bottom 35%) (its annual report).

From the record

Vertex Pharmaceuticals Incorporated's growth drivers, from the filed years to fiscal 2025: revenue grew 10.3% a year over the last three filed years against 24.2% over all 10, slowing (bottom 29% of its family); the newest year grew 8.9% (top 48%); research spending grew 15.5% a year (top 30%); capital spending grew 28.8% a year (top 20%) (its annual reports). Vertex Pharmaceuticals Incorporated reported 6 product lines in fiscal 2025: TRIKAFTAKAFTRIO at $10 billion (85%), ALYFTREK at $838 million (7%), Manufactured Product Other at $820 million (7%), and 3 more; 3 of 3 grew against the year before (its annual report).

From the record

Vertex Pharmaceuticals Incorporated's newest year against its own record: revenue of $12 billion in fiscal 2025 came in 2% below the $12 billion its prior three years' pace pointed to (bottom 50% of its family); net income of $4.0 billion against a prior three-year average of $2.1 billion (top 20%); a net margin of 32.9% against 23% before (bottom 49%) (its annual reports).